Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and Wegovy pens are available to eligible self-paying patients for $499-per-month through GoodRx, via a collaboration with Novo Nordisk (NVO), effective immediately. This collaboration “significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide,” and marks the first time Ozempic has been made available to patients at this self-pay price, according to GoodRx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target lowered to $37 from $48 at Truist
- Insider Moves: United, Devon, Datadog, Hims & Hers, fuboTV
- Here’s Why Wall Street Is Cautious on Hims & Hers Health Stock (HIMS)
- Hims & Hers calls Bloomberg story on FTC probe ‘rehashed’
- Hims & Hers probed by FTC over cancellation practices complaints, Bloomberg says